Onivyde 4.3 mg/mL

Onivyde 4.3 mg/mL is an injectable powder for solution, used for specific medical treatments. This formulation by Ipsen Biopharmaceuticals is designed for intravenous administration.

Onivyde 4.3 mg/mL is primarily used in combination with other medications for the treatment of advanced cancers. It is often prescribed for patients who have previously undergone other treatments. The active ingredient, irinotecan hydrochloride, is a chemotherapy agent that works by interfering with the growth of cancer cells.

Common effects of Onivyde 4.3 mg/mL may include nausea, vomiting, diarrhea, and fatigue. Some patients may experience more severe side effects, such as low blood cell counts or infections. It is important to discuss any unusual symptoms with a healthcare provider.

Onivyde 4.3 mg/mL should be handled with care, as it is a potent medication. It is essential to follow the prescribed dosage and administration instructions provided by a healthcare professional. Patients should be monitored regularly for any adverse reactions.

Onivyde 4.3 mg/mL may interact with other medications, including those that affect the liver or bone marrow. It is important to inform healthcare providers about all medications being taken to avoid potential interactions. Alcohol and certain foods may also affect the efficacy of the treatment.